{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:32:44Z","timestamp":1791567164733,"version":"4.3.4"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypereosinophilic syndromes (HES) are a heterogenous group of rare disorders with clinical manifestations ranging from fatigue to life-threatening endomyocardial fibrosis and thromboembolic events. Given the broad differential diagnosis of HES, a comprehensive approach is needed to identify potential secondary (treatable) causes and define end-organ manifestations. Classification by clinical HES subtype is also useful in terms of assessing prognosis and guiding therapy. Corticosteroids remain the mainstay of initial therapy in the setting of acute, life-threatening PDGFR mutation-negative HES. Whereas the recent availability of eosinophil-targeted therapies with extraordinary efficacy and little apparent toxicity is changing the treatment paradigm, especially for idiopathic HES and overlap syndromes, questions remain unanswered regarding the choice of agent, impact of combination therapies, and long-term effects of eosinophil depletion. This review provides a case-based discussion of the differential diagnosis of HES, including the classification by clinical HES subtype. Treatment options are reviewed, including novel eosinophil-targeted agents recently approved for the treatment of HES and\/or other eosinophil-associated disorders. Primary (myeloid) disorders associated with hypereosinophilia are not be addressed in depth in this review.<\/jats:p>","DOI":"10.1182\/hematology.2022000367","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:12:27Z","timestamp":1670584347000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Approach to the patient with suspected hypereosinophilic syndrome"],"prefix":"10.1182","volume":"2022","author":[{"given":"Amy D.","family":"Klion","sequence":"first","affiliation":[{"name":"Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"1","key":"2022120916091798000_hem2022000367C1","doi-asserted-by":"crossref","first-page":"2004101","DOI":"10.1183\/13993003.04101-2020","article-title":"Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study","volume":"57","author":"Sunadome","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"2022120916091798000_hem2022000367C2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2022120916091798000_hem2022000367C3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2022120916091798000_hem2022000367C4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2022120916091798000_hem2022000367C5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2022120916091798000_hem2022000367C6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2022120916091798000_hem2022000367C7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2022120916091798000_hem2022000367C8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med"},{"issue":"15","key":"2022120916091798000_hem2022000367C9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"2022120916091798000_hem2022000367C10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"2022120916091798000_hem2022000367C11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lef\u00e8vre","year":"2014","journal-title":"Medicine"},{"issue":"6","key":"2022120916091798000_hem2022000367C12","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jaip.2021.01.030","article-title":"CD3-CD4+ lymphocytic variant hypereosinophilic syndrome: diagnostic tools revisited","volume":"9","author":"Carpentier","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2022120916091798000_hem2022000367C13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaip.2019.08.049","article-title":"Assessment of T-cell polarization on the basis of surface marker expression: diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome","volume":"8","author":"Ledoult","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"2022120916091798000_hem2022000367C14","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.3390\/cells9091992","article-title":"Gene expression comparison between S\u00e9zary syndrome and lymphocytic-variant hypereosinophilic syndrome refines biomarkers for S\u00e9zary syndrome","volume":"9","author":"Moerman-Herzog","year":"2020","journal-title":"Cells"},{"issue":"8","key":"2022120916091798000_hem2022000367C15","first-page":"1086","article-title":"CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lef\u00e8vre","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"2022120916091798000_hem2022000367C16","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2022120916091798000_hem2022000367C17","doi-asserted-by":"crossref","first-page":"108982","DOI":"10.1016\/j.clim.2022.108982","article-title":"What we have learned about lymphocytic variant hypereosinophilic syndrome: a systematic literature review","volume":"237","author":"Shi","year":"2022","journal-title":"Clin Immunol"},{"key":"2022120916091798000_hem2022000367C18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2022120916091798000_hem2022000367C19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","author":"Chen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2022120916091798000_hem2022000367C20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaip.2022.01.043","article-title":"Controversies in allergy: the potential role of biologics as first-line therapy in eosinophilic disorders","volume":"10","author":"Dellon","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2022120916091798000_hem2022000367C21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"2022120916091798000_hem2022000367C22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"2022120916091798000_hem2022000367C23","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2022120916091798000_hem2022000367C24","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2022120916091798000_hem2022000367C25","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"17","key":"2022120916091798000_hem2022000367C26","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2022120916091798000_hem2022000367C27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"2022120916091798000_hem2022000367C28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid- sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"2022120916091798000_hem2022000367C29","article-title":"Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and IL-5 [published online ahead of print 12 May 2022]","author":"Rothenberg","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2022120916091798000_hem2022000367C30","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.17615","article-title":"Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis","volume":"195","author":"Williams","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2022120916091798000_hem2022000367C31","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2022120916091798000_hem2022000367C32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","article-title":"An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes","volume":"10","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2022120916091798000_hem2022000367C33","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MCHD-0020-2015","article-title":"The regulatory function of eosinophils","volume":"4","author":"Wen","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"3","key":"2022120916091798000_hem2022000367C34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00281-021-00849-w","article-title":"Lessons learned from targeting eosinophils in human disease","volume":"43","author":"Kuang","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"5","key":"2022120916091798000_hem2022000367C35","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2022120916091798000_hem2022000367C36","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2022120916091798000_hem2022000367C37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2022120916091798000_hem2022000367C38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase IIIb ALIZE trial","volume":"11","author":"Zeitlin","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"3","key":"2022120916091798000_hem2022000367C39","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2020.11.060","article-title":"Successful pregnancy in the setting of eosinophil depletion by benralizumab","volume":"9","author":"Manetz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2022120916091798000_hem2022000367C40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2022120916091798000_hem2022000367C41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.iac.2015.05.003","article-title":"Eosinophilia in infectious diseases","volume":"35","author":"O'Connell","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"2022120916091798000_hem2022000367C42","first-page":"1140","article-title":"Eosinophilia associated with immune deficiency","volume":"10","author":"Olbrich","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/47\/2021769\/47klion.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/47\/2021769\/47klion.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:12:56Z","timestamp":1670584376000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/47\/493536\/Approach-to-the-patient-with-suspected"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000367","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}